Study Title: Randomized Phase III Trial of M-Folfirinox +/- Nivolumab vs. Folfox +/- Nivolumab for First Line Treatment of Metastatic HER-2 Negative Gastroesophageal Addenocarcinoma
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Lockhart, Albert, at lockhara@musc.edu.Study Coordinator, Concepcion, Holly, at concepch@musc.edu.Trial opened at the following institutions: Medical University of South Carolina